A case-time-control study found no association between the initiation of interleukin 17 (IL-17) receptor A inhibitors and major adverse cardiovascular events (MACEs). Researchers conducted a case-time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback